The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
26653735 |
81 |
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. |
Pfizer |
26753813 |
22 |
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. |
University Of Minnesota |
25264600 |
64 |
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. |
Takeda Pharmaceutical |
25686153 |
73 |
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. |
University Of Navarra |
25192810 |
66 |
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site. |
Takeda Pharmaceutical |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University Of Florida |
18061445 |
103 |
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Research And Development |
22175825 |
19 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
Pfizer |
22017539 |
75 |
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. |
Boehringer Ingelheim Pharmaceuticals |
18790648 |
317 |
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. |
University Of Athens |
18442906 |
40 |
Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. |
North Dakota State University |
17276676 |
112 |
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16473009 |
23 |
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
11585440 |
76 |
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. |
Dupont Pharmaceuticals |
7932530 |
2 |
Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown. |
Dupont Pharmaceuticals |
21524149 |
13 |
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands. |
Suven Life Sciences |
8632342 |
110 |
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. |
Eli Lilly |
7651361 |
32 |
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. |
Georgetown University |